Skip to content

Imaging lithium in Alzheimer's disease

A 7Li-MRI study of brain lithium distribution in Alzheimer’s disease and healthy controls

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN18150075
Enrollment
20
Registered
2025-12-02
Start date
2025-09-08
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Specialty: Dementia and Neurodegeneration, Primary sub-specialty: Dementia

Interventions

This study is a feasibility study and will follow a longitudinal design using serial 7Li-MRI and structural MRI sequences. Participant recruitment: This study will recruit up to 20 subjects: 12 parti
MMSE score 16-24) and 8 healthy volunteers (matched on age and sex). Study design: The study will proceed in 2 phases. In study phase 1: Up to 4 people with Alzheimers disease will be recruited to c

Sponsors

Cumbria Northumberland Tyne and Wear NHS Foundation Trust
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: Healthy subjects 1. Aged 50-80 years old 2. No history of past or present major psychiatric or neurological disorders or mild cognitive impairment Patients only 1. Aged 50-80 years old 2. Diagnosis of Alzheimer’s disease – made by two independent clinicians based on McKhann criteria 3. Mild-moderate disease severity (Mini- Mental State Examination score 16-24) 4. No history of bipolar disorder, major depression or other neuropsychiatric conditions aside from Alzheimer’s disease

Exclusion criteria

Exclusion criteria: 1. Presence of contraindications to lithium treatment (such as renal failure, epilepsy or psoriasis) 2. Presence of contraindications to magnetic resonance imaging (such as pacemakers and other incompatible implants, claustrophobia) 3. Current treatment with lithium, non-steroidal anti-inflammatory drugs or ACE inhibitors 4. Lack of sufficient understanding of the nature of the study and any hazards of participating in it 5. Lack of ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire study 6. Lack of willingness to give written consent to participate after reading the information and consent forms, and after having the opportunity to discuss the study with the investigator or his delegate 7. Lack of capacity to provide informed consent, as judged by an investigator

Countries

England, United Kingdom

Contacts

Public ContactDavid Cousins
david.cousins@ncl.ac.uk+44(0)191 208 1152

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 14, 2026